Javascript must be enabled to continue!
Treatment: DMARDs
View through CrossRef
In axial spondyloarthritis (axSpA) there is little evidence to support use of classical synthetic disease-modifying antirheumatic drugs (DMARDs), with the majority of studies performed in advanced ankylosing spondylitis. Sulfasalazine is the best investigated DMARD in axSpA. Its positive clinical effect, if any, seems to be more prominent in the presence of peripheral arthritis, although a certain proportion of patients with axial disease might benefit from sulfasalazine therapy. Available data indicate that there is no evidence that methotrexate might be effective in axial disease, and only marginal evidence exists in support of methotrexate use in case of peripheral involvement. No true disease-modifying properties (e.g. retardation of structural damage progression in the spine) have been demonstrated for DMARDs in axSpA to date. Efficacy of a combination therapy (e.g. methotrexate plus sulfasalazine) as well as benefits of methotrexate (or other DMARDs) in addition to tumour necrosis factor α inhibitors in axSpA remain uncertain.
Title: Treatment: DMARDs
Description:
In axial spondyloarthritis (axSpA) there is little evidence to support use of classical synthetic disease-modifying antirheumatic drugs (DMARDs), with the majority of studies performed in advanced ankylosing spondylitis.
Sulfasalazine is the best investigated DMARD in axSpA.
Its positive clinical effect, if any, seems to be more prominent in the presence of peripheral arthritis, although a certain proportion of patients with axial disease might benefit from sulfasalazine therapy.
Available data indicate that there is no evidence that methotrexate might be effective in axial disease, and only marginal evidence exists in support of methotrexate use in case of peripheral involvement.
No true disease-modifying properties (e.
g.
retardation of structural damage progression in the spine) have been demonstrated for DMARDs in axSpA to date.
Efficacy of a combination therapy (e.
g.
methotrexate plus sulfasalazine) as well as benefits of methotrexate (or other DMARDs) in addition to tumour necrosis factor α inhibitors in axSpA remain uncertain.
Related Results
Biologic DMARDs (TNF inhibitors)
Biologic DMARDs (TNF inhibitors)
Tumor necrosis factor-α inhibitors (TNFi) can effectively treat all domains of disease in patients with psoriatic arthritis (PsA). They have been shown to be effective and also ge...
Vascular biology
Vascular biology
Vascular biology is the study of the physiology of the vasculature and how it may be the target for disease processes. An understanding of vascular biology is central to the study ...
Vascular biology
Vascular biology
Vascular biology is the study of the physiology of the vasculature and how it may be the target for disease processes. An understanding of vascular biology is central to the study ...
Vaccination in immunocompromised adults
Vaccination in immunocompromised adults
This chapter addresses all important questions regarding vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRD). First, the incidence of vaccine-preventabl...
Ankylosing spondylitis
Ankylosing spondylitis
Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly of the sacroiliac joint (SIJ) and the spine. It starts normally in the second decade of life and has a s...
Axial spondyloarthropathies
Axial spondyloarthropathies
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly of the sacroiliac joint (SIJ) and the spine. It starts normally in the second decade of life and has...
Dual diagnosis
Dual diagnosis
Substance abuse and mental illness are concentrated in correctional populations. Further, nearly half of female inmates and one-third of male inmates with substance use disorders h...
Values-Based Involuntary Seclusion and Treatment
Values-Based Involuntary Seclusion and Treatment
This chapter gives a reflective account of a values-based model of involuntary psychiatric seclusion and treatment (henceforth “involuntary treatment”) adopted in the training mate...

